CJC-1295 No DAC + Ipamorelin Blend Research Guide

By NorthPeptide Research Team · April 6, 2026

Growth hormone research has been shaped by a central challenge: how do you study GH axis biology without suppressing the body’s own production? Injecting exogenous GH solves the short-term measurement problem but disrupts the feedback loops that make GH physiology so interesting to study. Secretagogues — compounds that stimulate the pituitary to produce its own GH — offer a different approach.

CJC-1295 No DAC and Ipamorelin represent the two primary stimulatory pathways for GH release, arriving at the same endpoint through entirely different mechanisms. Understanding why they are combined requires understanding each one first.

Background: How Growth Hormone Is Regulated

The pituitary does not release growth hormone in a steady stream. It pulses — large bursts separated by troughs where GH is nearly undetectable. The biggest pulse happens during deep sleep, typically in the first few hours after falling asleep. Smaller pulses occur throughout the day, often triggered by exercise, fasting, or stress.

Three signals govern this pulsatile pattern:

1. GHRH (Growth Hormone-Releasing Hormone): Released from the hypothalamus, it drives the pituitary’s somatotroph cells to synthesize and release GH. This is the primary stimulatory signal.
2. Somatostatin: Also released from the hypothalamus, it acts as a brake — suppressing GH release between pulses. Somatostatin tone is what creates the troughs in the GH pulse pattern.
3. Ghrelin (and the GHS-R system): The “hunger hormone” has a secondary role as a GH secretagogue through a receptor system (GHS-R1a) entirely separate from GHRH. Ghrelin amplifies GH pulses, particularly when somatostatin tone is low, and also has direct effects on hypothalamic GHRH neurons.

CJC-1295 No DAC acts on pathway 1. Ipamorelin acts on pathway 3. They do not compete with each other — they converge on the same output (GH release) from different directions.

CJC-1295 No DAC: The GHRH Analog

What It Is and Why It Was Developed

Native GHRH is a 44-amino-acid peptide, but only the first 29 amino acids are needed for full biological activity. The problem with native GHRH(1-29) is that it is destroyed within minutes by dipeptidyl peptidase-4 (DPP-4), an enzyme that cleaves peptides at the position 2 amino acid. By the time you inject GHRH(1-29), most of it is inactivated before it reaches the pituitary.

CJC-1295 No DAC (also called Modified GRF 1-29 or Mod GRF 1-29) solves this with four strategic amino acid substitutions:

• Position 2: Alanine → Aminoisobutyric acid (Aib). Blocks DPP-4 cleavage.
• Position 8: Alanine → Aib. Further DPP-4 resistance.
• Position 15: Glycine → Alanine. Improves stability.
• Position 27: Methionine → Leucine. Prevents oxidation.

The result is a GHRH analog with a half-life of approximately 30 minutes — short enough to allow discrete pulsatile GH release, long enough to produce a meaningful biological effect at the pituitary.

Why “No DAC” Specifically?

There is also a CJC-1295 with DAC (Drug Affinity Complex), which uses a chemical linker to covalently bind to serum albumin after injection. Albumin binding extends the half-life from 30 minutes to approximately 6–8 days, creating a steady, sustained elevation of GH.

For combination use with Ipamorelin, the No DAC version is generally preferred in research protocols. Here is why: the goal of the combination is to recreate and amplify pulsatile GH secretion. When you administer CJC-1295 No DAC alongside Ipamorelin, you get a sharp GH pulse — a large spike followed by a return to baseline — which more closely mirrors how the pituitary naturally operates.

CJC-1295 with DAC, by contrast, keeps GH continuously elevated for most of the week. This chronic non-pulsatile elevation is associated with receptor desensitization over time and does not replicate physiological secretion patterns. For researchers studying GH axis biology or GH-dependent tissue effects in the context of normal physiology, the No DAC version’s pulse profile is more relevant.

Mechanism at the Pituitary

When CJC-1295 No DAC binds to GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary, it activates the Gs protein → adenylyl cyclase → cAMP → PKA signaling cascade. This cascade triggers GH vesicle exocytosis and also stimulates new GH gene transcription. The net effect is a dose-dependent increase in GH release that is subject to somatostatin inhibition — meaning pulsatility is preserved because the somatostatin brake still functions.

A pivotal 2006 clinical study in the Journal of Clinical Endocrinology & Metabolism evaluated CJC-1295 with DAC (to assess the amplified, sustained endpoint) and found 2- to 10-fold increases in mean GH concentration persisting up to 6 days after a single injection, with IGF-1 increases of 1.5- to 3-fold lasting 9–11 days. Critically, GH pulsatility was preserved — the pattern of peaks and troughs continued, with increased amplitude. (Ionescu & Frohman, JCEM 2006)

Ipamorelin: The Selective Ghrelin Mimetic

What Makes Ipamorelin Different from Earlier GHS-R Agonists

Ipamorelin is a pentapeptide (five amino acids: Aib-His-D-2Nal-D-Phe-Lys-NH2) that activates the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor that ghrelin, the “hunger hormone,” activates.

Before Ipamorelin, the main GHS-R agonists in research were GHRP-2 and GHRP-6. Both are effective GH releasers, but they came with off-target effects that complicated research interpretations:

• GHRP-6 significantly increases appetite (ghrelin’s most famous side effect) and elevates prolactin levels.
• GHRP-2 increases cortisol (via HPA axis stimulation) and prolactin at higher doses.
• Hexarelin is even more potent but with the most pronounced cortisol and prolactin effects.

In a landmark selectivity comparison study published in 1998, Ipamorelin was shown to produce GH release comparable to GHRP-6 in potency while having no significant effect on ACTH, cortisol, or prolactin — even at doses far exceeding those needed for GH release. (Raun et al., European Journal of Endocrinology 1998) Appetite effects were also minimal compared to GHRP-6.

This selectivity made Ipamorelin uniquely useful for studying pure GHS-R-mediated GH secretion without confounding variables from cortisol or prolactin changes.

Mechanism: Two Steps of GH Stimulation

Ipamorelin stimulates GH through two distinct anatomical sites:

1. Direct pituitary effect: Binds GHS-R1a on somatotroph cells and activates phospholipase C (PLC) → IP3/DAG → increased intracellular calcium → GH vesicle exocytosis. This is a different intracellular cascade than GHRH (which uses cAMP/PKA), which is why the two pathways are additive.
2. Hypothalamic effect: Activates GHRH-releasing neurons in the arcuate nucleus, amplifying the endogenous GHRH signal and reinforcing the pituitary’s GH release.

Additionally, Ipamorelin functionally opposes somatostatin — it reduces the inhibitory tone that somatostatin exerts between pulses, which lowers the threshold for GH secretion. This somatostatin antagonism is the third mechanistic element contributing to its GH-releasing activity.

GH Pulse Kinetics

Ipamorelin produces a rapid, high-amplitude GH pulse. After subcutaneous administration, GH peaks within 30–40 minutes and returns to near baseline within approximately 3 hours. This sharp, clean pulse profile is well-suited for pre-sleep or post-exercise research protocols where researchers want to study discrete GH pulses rather than sustained elevation.

Ipamorelin was taken into Phase II clinical trials by Helsinn Therapeutics for postoperative ileus — delayed gut motility following abdominal surgery. While the primary endpoint was GI function, the trials provided human pharmacokinetic and safety data confirming dose-dependent GH release with no clinically significant effects on cortisol, ACTH, or prolactin. (PMC5256428)

The CJC-1295 No DAC + Ipamorelin Combination: Why It Works

Dual Pathway Synergy

The scientific rationale for combining these two peptides is rooted in a well-established principle of GH physiology: GHRH and ghrelin receptor agonists produce synergistic, not merely additive, GH output.

Studies combining native GHRH with GHRP compounds consistently showed that the combined GH response was greater than the sum of each peptide administered alone. This synergy is explained by the converging mechanisms:

• CJC-1295 No DAC loads the somatotroph cell with GH synthesis machinery activated via cAMP/PKA.
• Ipamorelin simultaneously triggers calcium-mediated GH vesicle exocytosis via PLC/IP3 and reduces somatostatin brake via GHS-R1a activation at the hypothalamus.
• The two signals arrive at different parts of the same cell, complementing each other rather than competing.

The result: a GH pulse that exceeds what either peptide generates alone, while still looking like a physiological pulse — large amplitude, clean rise and fall, no sustained plateau.

Mechanistic Comparison Table

Why This Combination Over Alternatives

Researchers have several options when studying GH secretion. Here is how the CJC-1295 No DAC + Ipamorelin combination compares to alternatives:

• vs. GHRP-2 or GHRP-6 + GHRH: The older combinations work, but GHRP-6 confounds data with appetite stimulation and prolactin elevation. GHRP-2 introduces cortisol as a variable. The CJC + Ipamorelin combination is cleaner for studies where you want to isolate GH-specific effects.
• vs. CJC-1295 with DAC alone: DAC provides a week-long sustained GH elevation, useful for certain endpoints. But it does not model pulsatile GH physiology, and the sustained elevation may induce receptor tolerance over extended protocols. The No DAC + Ipamorelin combination better mimics natural pulsatile GH secretion.
• vs. Sermorelin + GHRP: Sermorelin (GHRH 1-29) is the most extensively studied GHRH analog, but its ~10-minute half-life means it is degraded very rapidly. CJC-1295 No DAC’s DPP-4 resistance gives it a substantially longer and more predictable research window.
• vs. Exogenous GH: Administering synthetic growth hormone directly bypasses the entire regulatory axis and suppresses endogenous GH production via negative feedback. Secretagogue combinations preserve the feedback system, making them more useful for models studying how the GH axis responds to stimulation rather than simply measuring downstream GH effects.

GH Pulse Patterns: What Research Documents

Understanding the pulse kinetics of the combined protocol is central to research design. Based on the individual peptide data and GHRH + GHS-R combination studies:

• Onset: GH begins rising within 15 minutes of administration for both peptides administered together.
• Peak: GH reaches maximum concentration approximately 30–45 minutes post-administration.
• Duration: GH remains meaningfully elevated for 1.5–2.5 hours, driven primarily by Ipamorelin’s ~2-hour active window.
• Return to baseline: GH returns to pre-administration baseline within approximately 3 hours.
• IGF-1 response: Because IGF-1 is produced by the liver in response to GH signaling and has a longer half-life (~15 hours), IGF-1 elevations persist longer than the GH pulse itself and accumulate with repeated administration.

This profile is consistent with the largest natural GH pulses observed during slow-wave sleep, which is why pre-sleep administration has been a common timing choice in research protocols — administering the combination shortly before sleep may amplify the natural nocturnal GH surge.

Research Dosing Protocols

The following dosing parameters are derived from published clinical research and are provided for research reference purposes only. They do not constitute medical advice or recommended protocols for any human use.

In most published GHRH + GHS-R combination research, the peptides are administered simultaneously in the same injection. The pre-mixed CJC-1295 No DAC + Ipamorelin Blend simplifies this protocol.

Research Applications

Body Composition Studies

GH is a key regulator of both lipolysis (fat breakdown) and lean mass maintenance. It activates hormone-sensitive lipase in adipose tissue and stimulates hepatic IGF-1 production, which drives protein synthesis in muscle. Researchers studying body composition parameters have used GH secretagogue combinations to investigate whether stimulating endogenous GH production affects fat mass, lean mass, and the ratio between them without the exogenous GH confound.

Age-Related GH Decline Models

GH secretion declines approximately 14% per decade after age 30. The amplitude of individual GH pulses decreases, though the number of pulses stays roughly constant. This decline is paralleled by changes in body composition, recovery capacity, and tissue repair speed that researchers associate with the GH/IGF-1 axis. The CJC-1295 + Ipamorelin combination has been studied as a model for investigating whether stimulating GH secretagogue pathways can restore pulse amplitude in aged subjects.

Recovery and Tissue Repair Models

GH has documented roles in collagen synthesis, fibroblast proliferation, and tissue remodeling. The combination has been used in research models examining tendon, ligament, and skeletal muscle repair processes where GH-dependent tissue regeneration is the study endpoint.

Sleep Architecture Studies

The largest GH pulse in any 24-hour period occurs during slow-wave (deep) sleep, typically in the first 1–2 hours after sleep onset. This makes the GH/sleep relationship a productive research area. Studies have examined whether GH secretagogue administration modulates slow-wave sleep architecture and whether the enhanced nocturnal GH pulse affects recovery parameters measured the following day.

Comparison Studies vs Single Secretagogues

A well-designed research application for the combination is direct comparison with individual components — verifying the synergy hypothesis in the specific model system being studied. Does the combined peptide truly produce more GH than either component alone in this particular research context? The cleanness of the CJC + Ipamorelin signal (no cortisol, prolactin, or major appetite confounds) makes it easier to attribute observed effects specifically to GH elevation.

Handling and Reconstitution

Both CJC-1295 No DAC and Ipamorelin are supplied as lyophilized (freeze-dried) powders. Proper handling is important for maintaining peptide stability and research reproducibility.

• Storage (lyophilized): -20°C in a sealed container. Protect from moisture and light. Stable for 24 months under proper conditions.
• Reconstitution: Use bacteriostatic water (for research use). Add diluent slowly along the vial wall. Do not shake vigorously — invert and gently swirl to dissolve.
• Storage (reconstituted): 2–8°C refrigerated. Use within 20–28 days.
• Combination vials: Pre-blended vials are reconstituted identically to single-peptide vials and can be stored by the same protocol.

Safety Profile Observed in Research

Both peptides have been evaluated in human clinical studies with favorable safety profiles. Key observations:

• Injection site reactions: Mild, transient erythema and induration at the injection site are the most commonly reported local effects, consistent with subcutaneous peptide administration generally.
• GH-related effects: At higher doses, effects consistent with elevated GH have been observed — transient fluid retention, joint stiffness, paresthesia (tingling). These are class effects seen across GH secretagogues and exogenous GH at supraphysiological concentrations.
• No pituitary suppression: Unlike exogenous GH, which suppresses the body’s own GH production via negative feedback at the hypothalamic level, secretagogue-stimulated GH leaves the feedback loop intact. The pituitary produces GH in response to stimulation rather than receiving it externally. This is considered a significant advantage in long-term research models where GH axis integrity is a study parameter.
• IGF-1 monitoring: IGF-1 rises with repeated secretagogue use because each GH pulse stimulates hepatic IGF-1 production. Sustained supraphysiological IGF-1 is a concern in some research contexts. Monitoring IGF-1 as a biomarker is standard in GH secretagogue research designs.
• No cortisol or prolactin changes: Unlike GHRP-2, GHRP-6, and hexarelin, neither CJC-1295 No DAC nor Ipamorelin produces significant cortisol or prolactin elevation at research doses. This is Ipamorelin’s key selectivity advantage and makes the combination substantially cleaner for endocrine research.

Comparison with Related GH Secretagogues

Current Limitations and Research Gaps

Despite the strong mechanistic rationale and supporting data from individual peptide studies, several gaps in the combination research deserve acknowledgment:

• Limited combination-specific clinical trials: Published human studies specifically designed to test CJC-1295 No DAC + Ipamorelin as a combination (rather than inferring from individual peptide data) are sparse. Most combination research exists in the preclinical and anecdotal literature.
• Long-term safety data: Multi-month studies in humans for the combination specifically are not well-represented in the peer-reviewed literature. This is an important gap for researchers designing longer-duration protocols.
• Optimal dose ratio: Whether a fixed molar ratio of CJC to Ipamorelin is optimal or whether this varies by research endpoint is not established from controlled trials. The pre-blended formulations use a ratio derived from typical research dosing but not formally optimized in comparative studies.
• Individual variability: GH secretagogue responses vary substantially between subjects based on age, baseline GH status, body composition, and genetic factors. This variability is relevant for interpreting results across different research subjects.

Summary of Key Research References